Saturday, September 6, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Kforce Shares Face Headwinds as Analysts Lower Targets

Robert Sasse by Robert Sasse
September 4, 2025
in Analysis, Dividends, MDAX & SDAX
0
Kforce Stock
0
SHARES
10
VIEWS
Share on FacebookShare on Twitter

Kforce Inc. is navigating a challenging market environment characterized by downward revisions in analyst price targets and persistent softness in staffing sector demand. Despite these pressures, the firm maintains its commitment to a consistent dividend policy, providing a key point of stability for its shareholders.

Quarterly Results Present a Mixed Picture

The company’s Q2 2025 financial performance revealed a complex scenario. Revenue reached $334.3 million, representing a sequential increase of 1.3% but a year-over-year decline of 6.2%. Earnings per share (EPS) came in at $0.59, slightly below the consensus expectation of $0.60.

Looking ahead, management issued Q3 guidance projecting revenue in the range of $324 million to $332 million. EPS is forecast to be between $0.53 and $0.61, indicating a continuation of the current cautious outlook.

Wall Street Sentiment Shifts

Market experts have adopted a more pessimistic stance. Truist Financial revised its price target downward from $50 to $46, while UBS Group made a more significant cut from $45 to $40. The current average price target sits at $52.33, with a wide range spanning from $40 to $71. The overall consensus rating for the stock remains at “Hold.”

Dividend Commitment Offers Stability

A central element of Kforce’s investor proposition remains its reliable dividend. The company declared a quarterly distribution of $0.39 per share, payable on September 26 to shareholders of record as of September 12.

Should investors sell immediately? Or is it worth buying Kforce?

  • Quarterly Dividend: $0.39 per share
  • Ex-Dividend Date: September 12, 2025
  • Payment Date: September 26, 2025
  • Annualized Dividend: $1.56
  • Dividend Yield: ~4.8%

A payout ratio of 65.27% is viewed as solid, underscoring the sustainability of these distributions even during periods of market volatility.

Technical and Fundamental Position

The stock is currently trading between $32.10 and $32.60, positioned well below its key moving averages. The 50-day moving average stands at $38.30, and the 200-day average is at $42.47. The 52-week high of $66.30 remains a distant point of comparison.

With a market capitalization of approximately $607 million and a P/E ratio of 12.18, the stock’s beta of 0.75 suggests it has been less volatile than the broader market. Institutional activity has been mixed; Magnetar Financial increased its stake, while Trefis issued an “Unattractive” rating, citing concerns over weak operational performance.

The focus now shifts to upcoming investor conferences scheduled for September 17 and 24. Management’s ability to articulate a convincing strategy for recovery will be critical, as the staffing industry faces continued headwinds and a near-term rebound is far from certain.

Ad

Kforce Stock: Buy or Sell?! New Kforce Analysis from September 6 delivers the answer:

The latest Kforce figures speak for themselves: Urgent action needed for Kforce investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 6.

Kforce: Buy or sell? Read more here...

Tags: Kforce
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

TG Therapeutics Stock
Analysis

TG Therapeutics Stock: Riding a Wave of Commercial Success

September 6, 2025
OceanFirst Stock
Analysis

OceanFirst’s Strategic Moves Amid Mixed Financial Performance

September 6, 2025
Eli Lilly Stock
Analysis

Lilly’s Oncology Breakthrough: Cancer Drug Designation Signals Pipeline Strength

September 6, 2025
Next Post
Poseida Therapeutics Stock

Roche Completes Landmark Acquisition of Biotech Innovator Poseida Therapeutics

National Healthcare Stock

National Healthcare Shares Face Pivotal Technical Battle

Pet Acquisition LLC Stock

Petco Shares Plummet Amid Escalating Class Action Pressure

Recommended

BLDR stock news

Prominent Financial Firm SG Americas Securities LLC Increases Stake in Builders FirstSource as Company’s Potential Growth Trajectory Shines

2 years ago
Science Applications Stock

Institutional Investors Defy Cautious Analyst Stance on Science Applications

1 week ago
Green energy

Breakthrough in Carbon Capture Technology by ESG Clean Energy Subsidiary of Camber Energy

2 years ago
Tesla Stock

Tesla’s Expansion Hits Speed Bumps in Key Markets

4 days ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

AAPL Adobe Alibaba Alphabet Amazon AMD AMZN Apple BA BioNTech Broadcom C Coinbase DIS Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSFT NIO Nvidia Opendoor Oracle Palantir PayPal Pepsi PLTR Realty Income Red Cat Robinhood Rocket Lab USA SMCI Strategy Tesla TSLA Unitedhealth Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Lilly’s Oncology Breakthrough: Cancer Drug Designation Signals Pipeline Strength

S&P 500 Snub Deals Major Blow to MicroStrategy’s Bitcoin Ambitions

Oxford Lane Capital Implements Reverse Stock Split to Address Share Price Decline

Kingsway Financial Services: A Tale of Conflicting Investor Sentiment

Mixed Signals Weigh on Ultrapar’s Stock Performance

Can Illumina’s Bold Protein Analysis Strategy Reverse Its Market Slide?

Trending

TG Therapeutics Stock
Analysis

TG Therapeutics Stock: Riding a Wave of Commercial Success

by Robert Sasse
September 6, 2025
0

TG Therapeutics is demonstrating extraordinary momentum, largely driven by the remarkable performance of its flagship therapy. While...

US Physical Therapy Stock

Mixed Signals Emerge as US Physical Therapy Posts Record Results Amid Insider Sales

September 6, 2025
OceanFirst Stock

OceanFirst’s Strategic Moves Amid Mixed Financial Performance

September 6, 2025
Eli Lilly Stock

Lilly’s Oncology Breakthrough: Cancer Drug Designation Signals Pipeline Strength

September 6, 2025
Strategy Stock

S&P 500 Snub Deals Major Blow to MicroStrategy’s Bitcoin Ambitions

September 6, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Recent News

  • TG Therapeutics Stock: Riding a Wave of Commercial Success September 6, 2025
  • Mixed Signals Emerge as US Physical Therapy Posts Record Results Amid Insider Sales September 6, 2025
  • OceanFirst’s Strategic Moves Amid Mixed Financial Performance September 6, 2025

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

© 2024 Stocks Today

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com